developed a new method to mass-produce cardiomyocytes from cell iPS.

Was developed by Prof. Fukuda Keio University School of Medicine, a new method for the mass production of cardiomyocytes from (induced pluripotent stem cells) iPS cells that are grown in a variety of cell. High safety compared with the conventional method, and the results to accelerate the application to regenerative medicine and treatment of severe heart failure. Was published in the electronic edition of the U.S. science journal Cell Sutemuseru dated 16.
not available to the cells of interest in making therapeutic cells from iPS cells, the establishment of a method for efficiently removed, the undifferentiated cell may turn into cancer cells was an issue.
Usually, whereas cells get energy from sugar, Prof. Fukuda, myocardial cells focused on the fact that the energy source can be lactic acid. After the somewhat differentiated cardiac muscle cells iPS, if you only lactic acid nutrition of the culture, undifferentiated cells are killed in a few days, he was only able to produce a nearly cardiomyocytes. Function normally when transplanted into the heart of the monkey, he did not become cancerous over even after March.
Also simple fabrication process, about 1% of the price of traditional culture. Professor Fukuda said, "could be solved in one fell swoop a major challenge quality, quantity, and cost." Also feel that I want to proceed to establish the basic technology for steady while I just concrete application to clinical is hope.




さまざまな細胞に成長させられるｉＰＳ細胞（人工多能性幹細胞）から心筋細胞を大量生産する新たな手法を慶応大医学部の福田教授らが開発した。従来法と比べて安全性が高く、重度心不全治療など再生医療への応用を加速する成果という。１６日付の米科学誌セル・ステムセル電子版に掲載された。
　ｉＰＳ細胞から治療用の細胞を作る際には、目的の細胞になれず、がん細胞に変わる恐れがある未分化細胞を、効率的に除去する方法の確立が課題だった。
　福田教授らは、細胞が通常、糖分からエネルギーを得るのに対して、心筋細胞は乳酸もエネルギー源にできることに着目。ｉＰＳ細胞を心筋にある程度分化させた後、培養液の栄養分を乳酸だけにすると、未分化細胞が数日で死滅し、ほぼ心筋細胞だけを作製できた。サルの心臓に移植すると正常に機能し、３カ月たってもがん化しなかった。
　作製工程も単純で、培養液の価格も従来の約１％。福田教授は「質、量、コストという大きな課題を一挙に解決できた」と話した。臨床への具体的な応用が願われるところですが基礎技術を確立しながら地道に進めてほしい気もしますね。